U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H21N7O2S
Molecular Weight 423.491
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GSK-1071306

SMILES

CN1N=C2C=C(NC3=CC=NC(NC4=CC=C(C)C(=C4)S(N)(=O)=O)=N3)C=CC2=C1C

InChI

InChIKey=XWOGXAVHJKKNPO-UHFFFAOYSA-N
InChI=1S/C20H21N7O2S/c1-12-4-5-15(11-18(12)30(21,28)29)24-20-22-9-8-19(25-20)23-14-6-7-16-13(2)27(3)26-17(16)10-14/h4-11H,1-3H3,(H2,21,28,29)(H2,22,23,24,25)

HIDE SMILES / InChI

Molecular Formula C20H21N7O2S
Molecular Weight 423.491
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Patents

Patents

Substance Class Chemical
Created
by admin
on Sat Dec 16 08:09:36 UTC 2023
Edited
by admin
on Sat Dec 16 08:09:36 UTC 2023
Record UNII
Z51V93OIDV
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GSK-1071306
Common Name English
PAZOPANIB METABOLITE M27
Common Name English
BENZENESULFONAMIDE, 5-((4-((2,3-DIMETHYL-2H-INDAZOL-6-YL)AMINO)-2-PYRIMIDINYL)AMINO)-2-METHYL-
Systematic Name English
GSK1071306
Code English
Code System Code Type Description
CAS
1252927-47-1
Created by admin on Sat Dec 16 08:09:36 UTC 2023 , Edited by admin on Sat Dec 16 08:09:36 UTC 2023
PRIMARY
FDA UNII
Z51V93OIDV
Created by admin on Sat Dec 16 08:09:36 UTC 2023 , Edited by admin on Sat Dec 16 08:09:36 UTC 2023
PRIMARY
CAS
1414375-48-6
Created by admin on Sat Dec 16 08:09:36 UTC 2023 , Edited by admin on Sat Dec 16 08:09:36 UTC 2023
NO STRUCTURE GIVEN
PUBCHEM
68319455
Created by admin on Sat Dec 16 08:09:36 UTC 2023 , Edited by admin on Sat Dec 16 08:09:36 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> METABOLITE INACTIVE
Four pazopanib metabolites (GSK1268992, GSK1268997, GSK1071306, and GW700201) have been identified. Only one of these metabolites (GSK1268997) has been shown to inhibit the proliferation of VEGF-stimulated human umbilical vein endothelial cells with potency similar to pazopanib.